Claims for Patent: 4,338,325
✉ Email this page to a colleague
Summary for Patent: 4,338,325
| Title: | PGI2 Pharmacologically acceptable salts |
| Abstract: | The present invention relates to PGI2 pharmacologically acceptable salts, having pharmacological activity. Particularly, the compounds described herein are useful as platelet aggregation inhibitors. |
| Inventor(s): | Roy A. Johnson, Frank H. Lincoln, John E. Pike |
| Assignee: | Pharmacia and Upjohn Co |
| Application Number: | US06/200,690 |
| Patent Claims: |
1. A composition of matter consisting essentially of a pharmacologically acceptable salt of a compound of formula I ##STR3## 2. A composition according to claim 1 wherein said pharmacologically acceptable salt is the benzyltrimethylammonium salt. 3. A composition according to claim 1 wherein said pharmacologically acceptable salt is the tetramethylammonium salt. 4. A composition according to claim 1 wherein said pharmacologically acceptable salt is the sodium salt. 5. A composition according to claim 4 in a free flowing powder form. 6. A parenteral pharmaceutical composition for inhibition of platelet aggregation characterized in being prepared from(1) a free flowing powder form of the sodium salt of PGI2, a compound of formula I ##STR4## and (2) a conventional pharmaceutical diluent for parenteral formulations, such that the sodium salt of PGI2 is present in said composition at a concentration sufficient to inhibit platelet aggregation upon administration of a said composition in a predetermined volume or at a predetermined rate. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch